The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery
Primary Purpose
Radiculopathy
Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Kenalog and Sensorcaine
Sponsored by
About this trial
This is an interventional treatment trial for Radiculopathy focused on measuring Radiculopathy, Sciatica, Lumbar Disc Herniation, Surgical Alternative
Eligibility Criteria
Inclusion Criteria:
- Age: 18-65
- Diagnosed with lower extremity radiculopathy (sciatica) secondary to a lumbar disc herniation
- Exhausted non-operative measures:
- Medication has not been helpful in treating the patient's pain/symptoms
- Modification of daily activities has not been helpful in treating the patient's pain/symptoms
- Physiotherapy has not been helpful in treating the patient's pain/symptoms.
- Patient of the Investigator
- Patient willing to proceed with surgical intervention
Exclusion Criteria:
- Age: < 18 or > 65
- Any patient who has not attempted conservative non-operative treatment for a minimum of 6 weeks
- Any patient who has not been deemed a surgical candidate
- Any patient who has a contraindication for surgery
- Any patient who has a contraindication for Kenalog or Sensorcaine
- Known sensitivity to medicinal or non-medicinal ingredients
- Systemic infection
- Idiopathic thrombocytopenic purpura
- Cerebrospinal diseases
- Pregnancy and nursing mothers
Sites / Locations
- Saint John Regional Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Kenalog and Sensorcaine
Saline
Arm Description
The following drugs will be administered during a one time injection of the appropriate spinal level based off clinical and radiographic information: Intervention: Kenalog 40 mg/ml and Sensorcaine 0.25% 1cc
Saline injections will be used to mimic the Steroid dose
Outcomes
Primary Outcome Measures
Surgical Avoidance
After a minimum 1 year follow-up of an SNRI, a statistical analysis will be conducted to determine group differences in surgical necessity
Secondary Outcome Measures
Subjective questionnaires
Each patient will be followed over their course of treatment and information pertaining to their pain and symptoms will be recorded using standard questionnaires such as the SF-36 Questionnaire, the Oswestry Disability Index, and the Visual Analogue Scale. Patient demographics, diagnosis, Worker's Compensation status, spinal levels treatment/outcome, and time from referral to treatment will also be evaluated.
Full Information
NCT ID
NCT01073995
First Posted
February 22, 2010
Last Updated
September 28, 2016
Sponsor
Horizon Health Network
1. Study Identification
Unique Protocol Identification Number
NCT01073995
Brief Title
The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery
Official Title
The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery in Patients With Lumbar Disc Herniations
Study Type
Interventional
2. Study Status
Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
November 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Horizon Health Network
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The median Orthopaedic surgery wait time in Canada is 36.7 weeks (Esmail 2008), thus there is a need to find alternative treatments for pathologies such as lumbar disc herniations (LDH). The literature has demonstrated that selective nerve root injections (SNRI) are able to alleviate sciatic symptoms caused by LDH (Riew 2006) and may be beneficial as an alternative to surgery. It is necessary to determine whether SNRIs provide significant symptom resolution alleviating the need for surgery, or to determine if their success is transient and delays the time to surgery. The purpose of the proposed study is to evaluate the success of SNRI in patients suffering with LDH and to determine which factors influence outcome. Over the span of 2 years, data from 100 patients will be collected. These patients will be surgical candidates and have exhausted all non-operative measures prior to receiving a SNRI. Upon first assessment, each eligible patient will be randomly assigned to the treatment (steroid) or control (saline) group. The patient and all treating physicians will be blinded to the treatment given. Each patient will be followed over their course of treatment and information pertaining to their pain and symptoms will be recorded using standard questionnaires. Patient demographics, diagnosis, Worker's Compensation status, spinal levels treatment/outcome, and time from referral to treatment will also be evaluated. The primary outcome measure will be defined as the avoidance of surgery.
Detailed Description
Patient Selection: All patients (ages 18-65 years) who have been diagnosed with lower extremity radiculopathy (sciatica) secondary to a lumbar disc herniation that have been referred for SNRI by the principal investigator (Dr. Neil Manson) will be asked to participate in the study. All patients will have exhausted non-operative measures.
Initial Assessment: During the initial office visit, patients will be assessed by the principle investigator for inclusion in the study. If the patient demonstrates interest in the proposed research they will be provided a Consent Form and given the opportunity to ask a Research Assistant questions regarding their participation.
. Injections: Standard procedures for SNRI will be used by the participating Radiologists in the Department of Radiology at the Saint John Regional Hospital. Each patient will be randomly assigned by a Research Assistant to either the treatment (Kenalog/Sensorcaine) or control (Saline) group. All treatments will be blinded to the treating physicians and the patient.
Injectates: Control Group: Saline Treatment Group: Kenalog 40cc/0.25% Sensorcaine
Follow up assessment: During a follow-up visit, patients will be re-assessed to determine the success of the injection. SNRI success will be determined by self-reported pain and symptom reduction. If the patient and principle investigator do not deem the injection successful, further treatment options will be discussed (second injection, surgery, etc) and follow-up evaluations will be scheduled.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Radiculopathy
Keywords
Radiculopathy, Sciatica, Lumbar Disc Herniation, Surgical Alternative
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
54 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Kenalog and Sensorcaine
Arm Type
Active Comparator
Arm Description
The following drugs will be administered during a one time injection of the appropriate spinal level based off clinical and radiographic information:
Intervention:
Kenalog 40 mg/ml and Sensorcaine 0.25% 1cc
Arm Title
Saline
Arm Type
Placebo Comparator
Arm Description
Saline injections will be used to mimic the Steroid dose
Intervention Type
Drug
Intervention Name(s)
Kenalog and Sensorcaine
Other Intervention Name(s)
Kenalog, Triamcinolone, Sensorcaine, Marcaine, Bupivacaine hydrochloride
Intervention Description
Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
Primary Outcome Measure Information:
Title
Surgical Avoidance
Description
After a minimum 1 year follow-up of an SNRI, a statistical analysis will be conducted to determine group differences in surgical necessity
Time Frame
5 years
Secondary Outcome Measure Information:
Title
Subjective questionnaires
Description
Each patient will be followed over their course of treatment and information pertaining to their pain and symptoms will be recorded using standard questionnaires such as the SF-36 Questionnaire, the Oswestry Disability Index, and the Visual Analogue Scale. Patient demographics, diagnosis, Worker's Compensation status, spinal levels treatment/outcome, and time from referral to treatment will also be evaluated.
Time Frame
5 Years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age: 18-65
Diagnosed with lower extremity radiculopathy (sciatica) secondary to a lumbar disc herniation
Exhausted non-operative measures:
Medication has not been helpful in treating the patient's pain/symptoms
Modification of daily activities has not been helpful in treating the patient's pain/symptoms
Physiotherapy has not been helpful in treating the patient's pain/symptoms.
Patient of the Investigator
Patient willing to proceed with surgical intervention
Exclusion Criteria:
Age: < 18 or > 65
Any patient who has not attempted conservative non-operative treatment for a minimum of 6 weeks
Any patient who has not been deemed a surgical candidate
Any patient who has a contraindication for surgery
Any patient who has a contraindication for Kenalog or Sensorcaine
Known sensitivity to medicinal or non-medicinal ingredients
Systemic infection
Idiopathic thrombocytopenic purpura
Cerebrospinal diseases
Pregnancy and nursing mothers
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neil A Manson, MD
Organizational Affiliation
Canada East Spine Centre
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Erin E Bigney, MA
Organizational Affiliation
Canada East Spine Center
Official's Role
Study Director
Facility Information:
Facility Name
Saint John Regional Hospital
City
Saint John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Manuscript preparation in progress
Learn more about this trial
The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery
We'll reach out to this number within 24 hrs